Skip to main content

Table 1 Patient demographics, disease parameters, and baseline biomarker serum concentrations from MOBILITY part A biomarker analysis

From: Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

  Placebo + MTX (n = 45) Sarilumab 150 mg q2w + MTX (n = 46) Sarilumab 200 mg q2w + MTX (n = 45) Totala (n = 136)
Baseline demographic and disease parameters
 Age, mean ± SD, years 54.7 ± 13.1 49.8 ± 12.7 48.4 ± 12.8 51.0 ± 13.1
 Sex, female, % 75.6 84.8 80.0 80.1
 Duration of RA, mean ± SD, years 8.0 ± 8.6 7.1 ± 6.7 6.4 ± 6.4 7.2 ± 7.3
 Anti-CCP antibody positive, %b 73.7 95.0 90.0 86.4
 Rheumatoid factor positive, % 66.7 87.0 88.9 80.9
 Tender joint count, mean ± SD 27.9 ± 17.0 28.1 ± 17.2 26.9 ± 14.6 27.7 ± 16.2
 Swollen joint count, mean ± SD 17.6 ± 12.3 18.3 ± 10.9 17.2 ± 9.3 17.7 ± 10.8
 CRP, mean ± SD, mg/dL 2.8 ± 2.8 2.6 ± 2.8 3.4 ± 4.4 3.0 ± 3.4
Baseline biomarker serum concentrations, median (quartile 1/quartile 3)
 C1M, ng/mL 198.1 (132.0/263.4) 179.6 (140.2/235.8) 172.3 (132.4/273.0) 179.6 (133.5/259.3)
 C2M, ng/mL 0.2 (0.2/0.3) 0.3 (0.2/0.3) 0.2 (0.2/0.4) 0.2 (0.2/0.3)
 C3M, ng/mL 45.6 (38.9/58.1) 47.6 (38.3/60.2) 47.9 (37.9/59.3) 47.5 (38.3/59.0)
 CRPM, ng/mL 17.3 (12.1/21.7) 16.5 (14.1/21.4) 16.3 (13.9/22.3) 16.7 (13.1/21.7)
  1. aAll patients receiving placebo, sarilumab 150 mg q2w, or sarilumab 200 mg q2w. bResults not available for the entire biomarker population. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CCP cyclic citrullinated peptide, CRPM C-reactive protein MMP-derived fragment, MMP matrix metalloproteinase, MTX methotrexate, q2w every 2 weeks, RA rheumatoid arthritis, SD standard deviation
\